Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
This is a cross-sectional, case-control, observational experimental design. The study will enroll subjects with multiple sclerosis (MS) and age/gender matched on a battery of neuropsychological cognitive tests and self-report measures of cognition.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
18-55 years old
Right handed
Capacity to provide informed consent and sign consent
Diagnosis of Relapsing Remitting MS that meets the revised McDonald Criteria (2010) within the last 10 years
EDSS 0- 5.5
You may not be if
Diagnosis of primary progressive MS
Contraindications for MRI
Subjects required to take medications known to either benefit or adversely affect cognition at the time of testing and impact neuroimaging
Non-MS neurological disorders
Other medical or psychiatric disorders likely to affect cognitive performance
Active immunodeficiency, chronic infections, or history or progressive multifocal leukoencephalopathy
Individuals with severe level of depression on the BDI-II or severe anxiety on the BAI
MS subjects who are actively experiencing acute exacerbation in symptoms and they must be at least 4 weeks free of steroid medication, are currently taking a chemotherapy agent, or have changed medication in the last two months
Subjects who fail symptom validity measures during neuropsychological testing will be excluded
Clareo Health | Allocentric Memory in MS and Resting State Functional MRI
